Abstract:

Introduction: Pancreatic cancers are ranked fourth among cancer-related death causes. Adjuvan chemotherapy (KT) and chemoradiotherapy (KRT) studies are carried out to improve overall survival. We also intended to investigate the effect of chemoradiotherapy in adjuvant treatment retrospectively in pancreatic cancer. Methods: The data of 90 patients operated due to pancreatic cancer in our centre between January 2010 and December 2017 and subsequently adjuvant treatment was scaned retrospectively. The patient’s records of age, gender, ECOG performance status, body mass index (BMI), stage, adjuvan period receiving therapies, whether or not the KRT was taken, were recorded and studied. In total, 46 patients were involved in the study. The average GSK in the KRT arm is 16.9 months (7.8-2,63 months) while the KT arm is 17.6 months and there is no statistically significant difference between the two groups (p=0.875). The average DFS was 12.2 months in the KRT arm, while the KT arm was 7.2 months (p:0,3). Debate: As a result, in accordance with the latest studies in literature, our study has also not shown the contribution to the overall survival and non-sick survival of additive chemotherapy to adjuvant treatment in patients with pancreatic cancer.

Keywords: